



Amarin Corporation plc
 Investor Relations Department
 2 Pembroke House, Upper
 Pembroke
 Street 28-32
 Dublin 2
 Ireland

[Visit IR website](#)

[Sign-up for Email alerts](#)

NASDAQ: AMRN

Last Trade:	3.40
Trade Time:	4:00 PM ET Mar 16, 2018
Change:	-0.14 (-3.955%)
Day Range	3.37 - 3.59
52-Week Range	2.85 - 4.60
Volume	1,611,668

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Mar 12, 2018*
[Vascepa® \(Icosapent Ethyl\) Showed Reductions in Potentially Atherogenic Lipids and Inflammatory Markers in Patients With Persistent High Triglycerides and Elevated High-Sensitivity C-Reactive Protein \(hsCRP\)](#)
- Mar 12, 2018*
[Real-World Data Supports Association Between Elevated Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs](#)
- Mar 5, 2018*
[Amarin Announces Closing of Underwriter's Purchase of Additional Shares](#)
- Mar 1, 2018*
[Amarin Announces Start of Final Clinical Site Visits in the REDUCE-IT Cardiovascular Outcomes Study](#)
- Feb 28, 2018*
[Amarin Sponsors Multiple Scientific Presentations Scheduled for 2018 American College of Cardiology Annual Scientific Session & Expo](#)

Financials [\[View all \]](#)

- [Fourth Quarter Financial Results](#)
- Feb 27, 2018*
[Annual Report \(10-K\)](#)
- Apr 21, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 1, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 2, 2017*
[Quarterly Report \(10-Q\)](#)
- May 3, 2017*
[Quarterly Report \(10-Q\)](#)